Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $208.59, Implies 44% Upside

What happened

The average price target for Neurocrine Biosciences stock from 28 analysts rose from $207.37 to $208.59, with forecasts ranging from $150 to $253 per share. Based on the Nov. 2 closing price, the new target implies about 44% potential upside.

Confirmed

Global impact / market context

A higher average target means analysts collectively expect more upside from the current share price. The 44% figure suggests they see the stock as undervalued, which can draw investor attention and support demand for the shares.

Analyst inference

The consensus rating stays at Buy across 31 analysts, split into 27 Buys, 4 Holds and 0 Sells. That near-unanimous positive view signals broad analyst confidence, though targets spread widely from $150 to $253, showing disagreement about the company's prospects.

Analyst inference

What to watch

1. Watch whether the average price target keeps rising from $208.59 or stalls, since the prior target was $207.37 and the range still spans $150 to $253. Confirmed
2. Track the analyst mix of 27 Buys, 4 Holds and 0 Sells for any downgrade that would weaken the consensus Buy rating across 31 covering analysts. Proposed
3. Compare the Nov. 2 closing price with the implied 44% upside, because a rising share price would shrink that gap and reduce the expected return analysts project. Analyst inference

Evidence

• Original source link unavailable